Showing results (171-180 of 588) with videos related to
Sort By:
Pageof 59
Cancer|May 21, 2011
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancerPatricia K Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, et al.International Journal of Cancer|March 27, 2023
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialElżbieta Senkus, Suzette Delaloge, Susan M Domchek, et al.Thoracic Cancer|August 16, 2022
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancerAlessandra Buja, Giulia Pasello, Marco Schiavon, et al.Expert Opinion on Therapeutic Targets|August 9, 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancerVanja Vaccaro, Davide Melisi, Emilio Bria, et al.Cancer|June 2, 2009
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trialsEmilio Bria, Federica Cuppone, Diana Giannarelli, et al.Translational Lung Cancer Research|January 23, 2016
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicitySara Pilotto, Miguel Angel Molina-Vila, Niki Karachaliou, et al.Cancers|March 29, 2023
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical SettingsPasquale Lombardi, Marco Filetti, Rosa Falcone, et al.Current Treatment Options in Oncology|February 22, 2019
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"Vincenzo Di Noia, Emanuele Vita, Miriam Ferrara, et al.Cancer Treatment Reviews|March 21, 2022
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysisPasquale Lombardi, Marco Filetti, Rosa Falcone, et al.Cancer Treatment Reviews|February 17, 2015
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trialsLuisa Carbognin, Isabella Sperduti, Rolando Nortilli, et al.Pageof 59